Clinical Trials in New York

Showing 20161-20180 of 22,668 trials

Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma

NCT00059904

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining rituximab with interleukin-2 may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with interleukin-2 in treating patients who have relapsed or refractory intermediate- or high-grade non-Hodgkin's lymphoma.

Lymphoma

Memorial Sloan Kettering Cancer CenterStarted Jan 2003

New York, New York, United States

TERMINATEDPhase 1< 1 mile

Occipital Nerve Stimulation in the Treatment of Migraine

NCT01855672

The objective of this proof-of-concept study is to generate initial safety and effectiveness data for the neuro-modulation stimulation (NMS) E-Box in patients with chronic migraine in an acute setting. The results of this study will determine if further development of this device in a larger study is warranted.

Migraine

Ethicon, Inc.1 participantsStarted Apr 2013

Newington, New Hampshire, United States • New York, New York, United States • Cincinnati, Ohio, United States +1 more locations

COMPLETED< 1 mile

Comparison of Aneuploidy Risk Evaluations

NCT01663350

This is a prospective, multi-center observational study designed to compare the test results of the Verinata Health Prenatal Aneuploidy Test to results of conventional prenatal screening for fetal chromosome abnormalities in 'all-risk' pregnancies.

PregnancyDown SyndromeEdwards Syndrome+2 more

Verinata Health, Inc.3,000 participantsStarted Jul 2012

San Diego, California, United States • Atlanta, Georgia, United States • Chicago, Illinois, United States +23 more locations

Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Occipital Nerve Stimulation in the Treatment of Migraine

Comparison of Aneuploidy Risk Evaluations

Find Trials by Condition in New York

Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate

Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix

Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

Neuropsychological Testing Using Mobile Devices

Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma

Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors

Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia